Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.
Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...
Adicionar um enredo no seu idiomaA marriage counselor's unusual method with a 2x4 gets him in trouble when one of his couples decides to get revenge.A marriage counselor's unusual method with a 2x4 ...
The Sonos Arc Ultra and the Sonos Beam 2 are sleek soundbars designed to elevate your home theater experience, but they differ in key ways. Firstly, the Sonos Arc Ultra is significantly larger ...
14, 2025 (GLOBE NEWSWIRE) -- Beam Global, (Nasdaq ... The CE mark enhances a manufacturer's reputation and builds consumer trust in the quality and safety of their products.
In the preceding three months, 4 analysts have released ratings for Beam Therapeutics (NASDAQ:BEAM), presenting a wide array of perspectives from bullish to bearish. The following table summarizes ...